| Title | Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study |
| Authors | Li, Xinjie Yin, Yue Cui, Qianqian Huang, Weijin Zou, Qinghua Shen, Tao |
| Affiliation | Peking Univ, Dept Microbiol, Sch Basic Med Sci, Beijing, Peoples R China Peking Univ, Sch Basic Med Sci, Infect Dis Ctr, Beijing, Peoples R China Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, NHC Key Lab Res Qual & Standardizat Biotech Prod, Beijing, Peoples R China Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, NMPA Key Lab Qual Res & Evaluat Biol Prod, WHO Collaborating Ctr Standardizat & Evaluat Biol, Beijing, Peoples R China |
| Issue Date | Nov-2022 |
| Publisher | JOURNAL OF MEDICAL VIROLOGY |
| Abstract | The long-term protective efficacy of neutralizing antibodies (Nabs) against Omicron subvariants after inactivated booster vaccines remains elusive. During the follow-up study, 54 healthy volunteers aged 20-31 years received inactivated CoronaVac booster vaccinations and were monitored for 221 days. The dynamic efficacy and durability of Nab against Omicron subvariants BA.1, BA.2, BA.2.12.2, and BA4/5 were assessed using a pseudotyped virus neutralization assay at up to nine time points post immunization. The antibody response against Omicron subvariants was substantially weaker than D614G, with BA.4/5 being the least responsive. The geometric mean titer (GMT) of Nab against Omicron subvariants BA.1, BA.2, BA.2.12.1, and BA.4/5 was 2.2-, 1.7-, 1.8-, and 2.2-fold lower than that against D614G (p(s) < 0.0001). The gap in Nab response between Omicron subvariants was pronounced during the 2 weeks-2 months following booster vaccination (p(s) < 0.05). Seven months post booster, the antibody potency against D614G was maintained at 100% (50% for Nab titers >= 100 50% inhibitory dilution [EC50]), whereas at 77.3% for BA.1, 90.9% for BA.2, 86.4% for BA.2.12.1, and 86.4% for BA.4/5 (almost 20% for Nab titers >= 100 EC50). Despite the inevitable immune escape, Omicron subvariants maintained sustained and measurable antibody potency post-booster vaccination during long-term monitoring, which could help optimize immunization strategies. |
| URI | http://hdl.handle.net/20.500.11897/658373 |
| ISSN | 0146-6615 |
| DOI | 10.1002/jmv.28279 |
| Indexed | SCI(E) |
| Appears in Collections: | 基础医学院 |
